InnFocus has nabbed a pair of strategic ophthalmic investors in its Series C financing for $32.8 million. The cash infusion will go to the final phase of clinical testing for the startup's MicroShunt, which is expected to be a minimally invasive alternative to surgery for primary open angle glaucoma.
Royal Philips has grand plans for growth in Israel. CEO Frans Van Houten opened up to Israeli newspaper Globes about the company's med tech ambitions in the country, months after Philips kicked off operations for a new technology incubator in Israel with partner Teva Pharmaceutical Industries.
Following up on data from a Phase I study in canines with osteosarcoma, Advaxis is taking its HER2 cancer vaccine into human trials.
Amid a growing body of research on heart health devices and blood pressure monitoring, a new report from Blue Cross Blue Shield shows that women undergo fewer diagnostic procedures and treatments following a heart attack than men.
How will Google Life Sciences create its highly anticipated nanotech diagnostic hordes? Precision NanoSystems might know. It's nabbed a $13.4 million Series A round to back its NanoAssemblr platform that can be used to create next-gen nanoparticle therapeutic and diagnostic agents targeted to the cellular level.
As medical experts question the efficacy of mammograms in breast cancer screening, a new study shows that computer-aided detection technology used during the process does not help spot cancer in patients.
Payers unhappy with the cost of new PCSK9 drugs are getting some ammo, as top U.S. physicians are recommending against using the drugs in a large patient pool.
Boston Scientific is launching an upper GI endoscopic surgical tool just as it has committed to become a founding sponsor of California healthcare incubator The Innovation Lab. The device is the Captivator for endoscopic mucosal resection, a minimally invasive alternative to a surgical procedure that removes part of the esophagus in upper gastrointestinal tract cases. The tool enables the staging and removal of precancerous tissue or early esophageal cancer.
Immunizing pregnant women with an RSV vaccine charged up levels of antibodies that should be able to protect infants during the first few months of their lives, Novavax reported Tuesday morning, adding that the Bill & Melinda Gates Foundation followed up with an $89 million grant to fund a pivotal study.
Eli Lilly and Incyte are now three for three Phase III studies for baricitinib, an oral JAK inhibitor for rheumatoid arthritis that is on track for a marketing application and a real-world test of its lofty blockbuster reputation with analysts--while one already established rival from Pfizer lags well behind expectations.